Markus KRAMBERG,Markus REY,Markus RIEDERER,Martine BAUMANN,Sebastien ROUX
申请号：
MX2019009559
公开号：
MX2019009559A
申请日:
2018.03.14
申请国别(地区):
MX
年份:
2019
代理人:
摘要：
The present invention relates to a P2Y12 receptor antagonist selected from the group consisting of4-((R)-2-{[6-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimid ine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carbo xylic acid butyl ester, (1S,2S,3R,5S)-3- [7-[(1R,2S)-2-(3,4-difluorophenyl)cyclopropylamino]-5-(propylth io)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy) cyclopentane-1,2-diol, and (1S,2R,3S,4R)-4-[7- [(1R,2S)-2-(3,4-difluorophenyl)cyclopropylamino]-5-(propylthio) -3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]cyclopentane-1,2,3-trio l, or a pharmaceutically acceptable salt thereof, for use as a medicament by subcutaneous or intradermal administration.La presente invención se refiere a un antagonista del receptor P2Y12 que se selecciona a partir del grupo que consiste en butil-éster del ácido 4-((R)-2-{[6-((S)-3-metoxi-pirrolidin-1-iI)- 2-fenil-pirimidin-4-carbonil]-amino}-3-fosfono-propionil)-piperaz in-1-carboxílico, (1S,2S,3R,5S)-3-[7-[(1R,2S)-2-(3,4-difluoro-feni l)-ciclopropil-amino]-5-(tiopropil)-3H-[1,2,3]-triazolo-[4,5-d]-p irimidin-3-iI]-5-(2-hidroxi-etoxi)-ciclopentano-1,2-diol, y (1S,2R,3S,4R)-4-[7-[(1R,2S)-2-(3,4-difluoro-fenil)-ciclopropil-am ino]-5-(tiopropil)-3H-[1,2,3]-triazolo-[4,5-d]-pirimidin-3-iI]-ci clopentano-1,2,3-triol, o una sal farmacéutica-mente aceptable de los mismos, para usarse como un medicamento a través de la administración subcutánea o intra-dérmica.
